Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ASTX660 is an orally bioavailable dual antagonist of cIAP and XIAP.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 17,500 | |||
5 mg | 在庫あり | ¥ 34,000 | |||
10 mg | 在庫あり | ¥ 52,500 | |||
25 mg | 在庫あり | ¥ 104,500 | |||
50 mg | 在庫あり | ¥ 154,500 | |||
100 mg | 在庫あり | ¥ 219,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 40,500 |
説明 | ASTX660 is an orally bioavailable dual antagonist of cIAP and XIAP. |
In vitro | Twenty-one triple-negative breast cancer (TNBC) cell lines are treated with ASTX660 in vitro and it is found that 43% are sensitive to ASTX660. |
In vivo | ASTX660 (daily oral treatment) inhibits tumor growth moderately but not a regression in HCC1806 xenografts in mice. |
分子量 | 539.68 |
分子式 | C30H42FN5O3 |
CAS No. | 1799328-86-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 47 mg/mL(87.09 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ASTX660 1799328-86-1 Apoptosis IAP ASTX-660 Inhibitor inhibit ASTX 660 inhibitor